Meeting
2020 Gastrointestinal Cancers Symposium
Association of objective response by mRECIST with better overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with systemic therapies: A systematic review and meta-analysis of randomized controlled trials.
Authors
Masatoshi Kudo
Kindai University Faculty of Medicine, Osaka, Japan
Masatoshi Kudo , Yasutaka Chiba , Tim Meyer , Riccardo Lencioni , Josep M. Llovet
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Other
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 586)
Abstract #
586
Poster Bd #
F3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of frontline systemic therapy for advanced hepatocellular carcinoma (aHCC): A network meta-analysis of landmark phase III trials.
First Author: Claudia A.M. Fulgenzi
Poster
2020 ASCO Virtual Scientific Program
Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
First Author: Arndt Vogel
Poster
2018 Genitourinary Cancers Symposium
Adjuvant antiangiogenic agents in post-nephrectomy renal cell carcinoma (RCC): A systematic review and meta-analysis.
First Author: Mohamad Bassam Sonbol
Poster
2024 ASCO Annual Meeting
Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.
First Author: Ghassan K. Abou-Alfa